US Broker Ratings

Owens & Minor, Inc. (OMI) Stock Analysis: Navigating Challenges with a Promising 14.73% Upside

Owens & Minor, Inc. (NYSE: OMI), a key player in the healthcare sector, particularly within the medical distribution industry, offers a blend of opportunities and challenges for investors. With a..

Celcuity Inc. (CELC) Stock Analysis: A 110% Upside Potential in Biotechnology

For investors with a keen eye on the healthcare sector, particularly biotechnology, Celcuity Inc. (NASDAQ: CELC) represents a compelling opportunity. The Minnesota-based clinical-stage biotech company is currently focused on innovative..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Unlocking a 59.85% Potential Upside in Biotechnology

For biotechnology investors seeking promising opportunities in the healthcare sector, Maze Therapeutics, Inc. (NASDAQ: MAZE) presents an intriguing proposition with a notable potential upside of 59.85%. This clinical-stage biopharmaceutical company,..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Volatility in the Biotech Sector

Ginkgo Bioworks Holdings, Inc. (NASDAQ: DNA) is a compelling entity in the biotechnology industry, offering a unique proposition with its cell engineering and biosecurity solutions. As the company continues to..

MeiraGTx Holdings plc (MGTX) Stock Analysis: A Biotech Gem with 219% Potential Upside

MeiraGTx Holdings plc (NASDAQ: MGTX) has emerged as a captivating player in the biotechnology sector, capturing the attention of investors with its promising pipeline of gene therapy treatments and a..

Sana Biotechnology, Inc. (SANA) Stock Analysis: Exploring a Potential 129.88% Upside in the Biotech Sector

Sana Biotechnology, Inc. (NASDAQ: SANA) is making waves in the biotechnology sector, with a market capitalization of $918.01 million. As a company focused on the innovative use of engineered cells..

EyePoint Pharmaceuticals, Inc. (EYPT): A Biotechnology Stock with a Compelling 186% Upside Potential

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a promising player in the biotechnology sector, is capturing the attention of investors with its robust pipeline and a striking potential upside of 186.55%. Headquartered..

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Exploring a 50% Potential Upside

Theravance Biopharma, Inc. (NASDAQ: TBPH), a dynamic player in the biotechnology sector, has been garnering attention from investors seeking substantial growth potential in the healthcare industry. The company, with a..

Opthea Limited (OPT) Stock Analysis: Healthcare Innovator Faces a Critical Phase Amid -60.90% Potential Downside

Investors with a keen interest in biotechnology and healthcare are no strangers to the speculative nature of investing in clinical-stage biopharmaceutical companies. Opthea Limited (NASDAQ: OPT), headquartered in South Yarra,..

Cel-Sci Corporation (CVM): Analyzing the 6,183% Upside Potential in Biotechnology

For investors with an appetite for high-risk, high-reward opportunities, Cel-Sci Corporation (NASDAQ: CVM) presents a compelling case. Operating within the healthcare sector and more specifically, the biotechnology industry, Cel-Sci is..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Biotechnology Innovator with a Remarkable 194% Upside Potential

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company, is drawing significant attention from investors with its innovative approach to precision medicine and a striking potential upside of 194.36%. Headquartered..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 38% Potential Upside with Strategic Diagnostics

For investors eyeing opportunities in the healthcare sector, Myriad Genetics, Inc. (NASDAQ: MYGN) presents a compelling case with its molecular diagnostic offerings. Despite facing challenges, the company’s strategic positioning in..

CorMedix Inc. (CRMD): Investor Outlook Reveals a Promising 62% Potential Upside

CorMedix Inc. (NASDAQ: CRMD), a key player in the biotechnology sector, is garnering attention from investors with an impressive potential upside of 62.25%. This biopharmaceutical company, headquartered in Berkeley Heights,..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: 231% Potential Upside Beckons Investors

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is capturing significant attention in the biotechnology sector, thanks to its impressive potential upside of 231%. This clinical-stage biopharmaceutical company is dedicated to developing innovative..

SIGA Technologies Inc. (SIGA) Stock Analysis: Unpacking the Forward P/E of 4.08 in a Volatile Healthcare Market

SIGA Technologies Inc. (NASDAQ: SIGA), a leading player in the health security market with a focus on antiviral treatments, presents a unique proposition for investors, particularly given its remarkably low..

iRadimed Corporation (IRMD) Stock Analysis: Exploring a 19% Upside Potential in the Healthcare Sector

iRadimed Corporation (NASDAQ: IRMD), a leading player in the healthcare sector, has been making waves with its innovative medical devices that cater specifically to the magnetic resonance imaging (MRI) market...

Immunome, Inc. (IMNM)

⚠️ No article content returned.

..

Tectonic Therapeutic, Inc. (TECX): Investor Outlook with a Staggering 279% Potential Upside

Tectonic Therapeutic, Inc. (NASDAQ: TECX), a promising player in the biotechnology sector, is capturing attention with a potential upside of 279.07%, according to analysts. Specializing in the discovery and development..

Septerna, Inc. (SEPN) Stock Analysis: Exploring the 107.62% Potential Upside in Biotechnology

Septerna, Inc. (NASDAQ: SEPN), a promising player in the biotechnology sector, stands at the intersection of innovation and opportunity, with a striking potential upside of 107.62% according to analyst estimates...

Castle Biosciences, Inc. (CSTL) Investor Outlook: Analyzing a Potential 80.89% Upside

Castle Biosciences, Inc. (NASDAQ: CSTL) emerges as a compelling opportunity within the healthcare sector, specifically in the diagnostics and research industry. Headquartered in Friendswood, Texas, this molecular diagnostics company focuses..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds